The remarkable ability of thiazolidinediones (TZDs), which are exogenous agonists of peroxisome proliferator-activated receptor gamma (PPARγ), to reduce proteinuria and improve renal pathological features, makes them a promising therapeutic drug for DN. The gene discussed is PPARG; the disease is liver dysplastic nodule.